GENETIC ASPECTS OF PROGNOSIS OF EFFICIENCY AND SAFETY OF PHARMACOTHERAPY OF ATOPIC BRONCHIAL ASTHMA IN CHILDREN


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents data on the effectiveness of pharmacogenetic markers of treatment efficacy in children with atopic bronchial asthma. Variability in response to treatment with glucocorticosteroids, leukotriene receptor antagonists and ß2-adrenergic agonists in children with bronchial asthma is disclosed. The association of Gly/Gly16 genotype of ß2-adrenergic receptor gene with insufficient effect of the therapy with short-acting ß2-agonists is demonstrated. The involvement of Gly16 allele, CYP2D6*1934GGd, in development of phenotype with severe asthma tolerant to therapy with ß2-agonists and inhaled corticosteroids is emphasized.

Full Text

Restricted Access

About the authors

I. I Balabolkin

FSAI “Scientific Center of Children's Health" of RMH

Moscow

V. A Bulgakova

FSAI “Scientific Center of Children's Health" of RMH

Email: irvilbulgak@mail.ru
MD, pediatrician of the highest qualification category, with additional specialization in allergology and immunology, clinical pharmacology; Chief Researcher Moscow

References

  1. Wenzel S. Phenotypes and endotypes: emerging concepts on asthma heterogeneity. Global Atlas of Asthma. Ed. Cezmi A. Akdis, Ioana Agache. 2013. P 34-35.
  2. Moffatt M.F., Kabesch M., Liang L., Dixon A.L., StrachanD, Heath S.,DepnerM.,vonBerg A., Bufe A., Rietschel E., et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature. 2007; 448: 470-73.
  3. Miller S.M., Ortega V.E. Pharmacogenetics and the development of personalized approaches for combination therapy in asthma. Curr. Allergy Asthma Rep. 2013; 13(5): 443-52.
  4. Ortega V.E., Meyers D.A., Bleecker E.R. Asthma pharmacogenetics and the development of genetic profiles for personalized medicine. Pharmgenomics Pers. Med. 2015; 8: 9-22.
  5. Drysdale C.M., McGraw D.W., Stack C.B., Stephens J.C., Judson R.S., Nandabalan K., Arnold K., Ruano G., Liggett S.B. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci USA. 2000; 97(19): 10483-88.
  6. Malmstrom K., Rodriguez-Gomez G., Guerra J., Villaran C., Pineiro A., Wei L.X., Seidenberg B.C., Reiss T.F. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann. Intern. Med. 1999; 130(6): 487-95.
  7. Silverman E.S., Liggett S.B., Gelfand E.W., Rosenwasser L.J., Baron R.M., Bolk S., Weiss S.T., Drazen J.M. The pharmacogenetics of asthma: a candidate gene approach. Pharmacogenomics J. 2001; 1: 27-37.
  8. Weiss S.T, Tantisira K. Pharmacogenetics of asthma. Global Atlas of Asthma. Ed. Cezmi A. Akdis, Ioana Agache; 2013. P. 25-27.
  9. TseS.M., Tantisira K., WeissS.T. The pharmacogenetics and pharmacogenomics of asthma therapy. Pharmacogenomics J. 2011; 11(6): 383-92.
  10. Балаболкин И.И., Булгакова В.А. Бронхиальная астма у детей. М., 2015. 144 с.
  11. Жданова М.В., Богданова М.А., Войтович А.Н., Ащепкова О.М., Журавская Е.Э., Трофимова Н.В., Новик Г.А., Ларионова В.И. Особенности течения бронхиальной астмы у детей с различными генотипами Bcll полиморфизма гена глюкокортикоидного рецептора. Педиатрия им. Г.Н. Сперанского. 2007; 86(4): 19-24.
  12. Szefler S.J., Martin R.J., King T.S., Boushey H.A., Cherniack R.M., Chinchilli V.M., Craig T.J., Dolovich M., Drazen J.M., Fagan J.K., Fahy J.V, Fish J.E., Ford J.G., Israel E., Kiley J., Kraft M., Lazarus S.C., Lemanske R.F Jr, Mauger E., Peters S.P, Sorkness C.A.; Asthma Clinical Research Network of the National Heart Lung, and Blood Institute. Significant variability in response to inhaled corticosteroids for persistent asthma. J. Allergy Clin. Immunol. 2002; 109(3): 410-18.
  13. Adcock I.M., Ford P.A., Bhavsar P., Ahmad T., Chung K.F. Steroid resistance in asthma: mechanisms and treatment options. Curr. Allergy Asthma Rep. 2008; 8(2): 171-78.
  14. Barnes P.J. Corticosteroid resistance in airway disease. Proc. Am. Thorac. Soc. 2004; 1(3): 264-68.
  15. Stevens A., Ray D.W., Zeggini E., John S., Richards H.L., Griffiths C.E. M., Donn R. Glucocorticoid sensitivity is determined by a specific glucocorticoid receptor haplotype. J. Clin. Endocrinol. Metab. 2004; 89(2): 892-97.
  16. Tantisira K.G., Weiss S.T. The pharmacogenetics of asthma: an update. Curr. Opin. Mol. Ther. 2005; 7(3): 209-17.
  17. Tantisira K.G., Silverman E.S., Mariani T.J., Xu J., Richter B.G., Klanderman B.J., Litonjua A.A., Lazarus R., Rosenwasser L.J., Fuhlbrigge A.L., Weiss S.T. FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma. J. Allergy Clin. Immunol. 2007; 120(6): 1285-91.
  18. Tantisira K.G., Lake S., Silverman E.S., Palmer L.J., Lazarus R., Silverman E.K., Liggett S.B., Gelfand E.W., Rosenwasser L.J., Richter B., Israel E., Wechsler M., Gabriel S., Altshuler D., Lander E., Drazen J., Weiss S.T. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet. 2004; 13(13): 1353-59.
  19. Tantisira K.G., Lazarus R., Litonjua A.A., Klanderman B., Weiss S.T. Chromosome 17: association of a large inversion polymorphism with corticosteroid response in asthma. Pharmacogenet Genomics. 2008; 18(8): 733-37.
  20. Hakonarson H., Bjornsdottir U.S., Halapi E., Bradfield J., Zink F., Mouy M., Helgadottir H., Gudmundsdottir A.S., Andrason H., Adalsteinsdottir A.E., Kristjansson K., Birkisson I., Arnason T., Andresdottir M., Gislason D., Gislason T., Gulcher J.R., Stefansson K. Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc. Natl. Acad. Sci. USA. 2005; 102(41): 14789-94.
  21. Muijsers R.B., Noble S. Montelukast: a review of its therapeutic potential in asthma in children 2 to 14 years of age. Paediatr Drugs. 2002; 4(2): 123-39.
  22. Ghiro L., Zanconato S., Rampon O., Piovan V., Pasquale M.F., Baraldi E. Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children. Eur. Respir. J. 2002; 20(3): 630-34.
  23. Knorr B., Matz J., Bernstein J.A., Nguyen H., Seidenberg B.C., Reiss T.F., Becker A. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. PediatricMontelukast Study Group. JAMA. 1998; 279(15): 1181-86.
  24. Knorr B., Franchi L.M., Bisgaard H., Vermeulen J.H., LeSouef P., Santanello N., Michele T.M., Reiss T.F., Nguyen H.H., Bratton D.L. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001; 108(3): E48.
  25. Bisgaard H., Zielen S., Garcia-Garcia M.L., Johnston S.L., Gilles L., Menten J., Tozzi C.A., Polos P Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am. J. Respir. Crit. Care Med. 2005; 171(4): 315-22.
  26. Балаболкин И.И., Смирнов И.Е., Ляпунов А.В. Лукина О.Ф., Горюнов А.В., Гончарова Н.В., Реутова B.C. Эффективность лечения монтелукастом детей с бронхиальной астмой. Вопросы современной педиатрии. 2006; 5(5): 35-8.
  27. Lima J.J., Zhang S., Grant A., Shao L., Tantisira K.G., Allayee H., Wang J., Sylvester J., Holbrook J., Wise R., Weiss S.T., Barnes K. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am. J. Respir. Crit. Care Med. 2006; 173(4): 379-85.
  28. Telleria J.J., Blanco-Quiros A., Varillas D., Armentia A., Fernandez-Carvajal I., Jesus Alonso M., Diez I. ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir Med. 2008; 102(6): 857-61.
  29. Mougey E.B., Lang J.E., Wen X., Lima J.J. Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J. Clin. Pharmacol. 2011; 51(5): 751-60.
  30. Булгакова В.А. Модификация терапии бронхиальной астмы. возможности повышения эффективности лечения вирус-индуцированной астмы у детей. Фарматека. 2015; (4): 6-12.
  31. Васьковский Н.В., Огородова Л.М., Фрейдин М.Б., Серебров В.Ю., Петровский Ф.И., Деев И.А. Роль полиморфизма гена ß2-адренергического рецептора в развитии бронхиальной астмы. Медицинская генетика. 2006; 1: 10-14.
  32. Green S.A., Turki J., Innis M. and Liggett S.B. Amino-terminal polymorphisms of the human ß2-adrenergic receptor impart distinct agonistpromoted regulatory properties. Biochemistry. 1994; 33: 9414-19.
  33. Martinez F.D., Graves P.E., Baldini M., Solomon S., Erickson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. 1997; 100(12): 3184-88.
  34. Turner S.W., Khoo S.K., Laing I.A., Palmer L.J., Gibson N.A., Rye P, Landau L.I., Goldblatt J., Le Souëf PN. ß2-adrenoceptor Arg16Gly polymorphism, airway responsiveness, lung function and asthma in infants and children. Clin Exp Allergy. 2004; 34(7): 1043-48.
  35. Брянцева О.Н., Тихомиров Е.Е., Журкова Н.В., Вознесенская Н.И., Баязутдинова Г.М., Аверьянова Н.С., Балаболкин И.И., Пинелис В.Г. Полиморфизм гена ß2-адренергического рецептора и эффективность бронхолитической терапии у детей с бронхиальной астмой. Педиатрическая фармакология. 2007; 4(3): 35-9.
  36. Wechsler M.E., Lehman E., Lazarus S.C., Lemanske R.F. Jr, Boushey H.A., Deykin A., Fahy J.V., Sorkness C.A., Chinchilli V.M., Craig T.J., DiMango E., Kraft M., Leone F., Martin R.J., Peters S.P, Szefler S.J., Liu W., Israel E.; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am. J. Respir. Crit. Care Med. 2006; 173(5): 519-26.
  37. Pillai S.G., Chiano M.N., White N.J., Speer M., Barnes K.C., Carlsen K., Gerritsen J., Helms P, Lenney W., Silverman M., Sly P., Sundy J., Tsanakas J., von Berg A., Whyte M., Varsani S., Skelding P., Hauser M., Vance J., Pericak-Vance M., Burns D.K., Middleton L.T., Brewster S.R., Anderson W.H., Riley J.H. A genome-wide search for linkage to asthma phenotypes in the genetics of asthma international network families: evidence for a major susceptibility locus on chromosome 2p. Eur. J. Hum. Genet. 2006; 14(3): 307-16. Erratum in: Eur. J. Hum. Genet. 2007; 15(6): 714.
  38. Балаболкин И.И., Тюменцева Е.С. Генетика атопических болезней у детей. Вестник Российской академии медицинских наук. 2010; (4): 15-22.
  39. Shin J., Kayser S.R., Langaee T.Y. Pharmacogenetics: from discovery to patient care. Am. J. Health Syst. Pharm. 2009; 66(7): 625-37.
  40. Stallings S.C., Huse D., Finkelstein S.N., Crown W.H., Witt W.P, Maguire J., Hiller A.J., Sinskey A.J., Ginsburg G.S. A framework to evaluate the economic impact of pharmacogenomics. Pharmacogenomics. 2006; 7(6): 853-62.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies